NextCure Inc (NXTC) Prix

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.